Incorrect description of mode of excretion of linagliptin

Por Woerle, Hans-Juergen, Patel, Sanjay
Publicado em 2010

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

Por von Eynatten, Maximilian, Gong, Yan, Emser, Angela, Woerle, Hans-Juergen
Publicado em 2013

The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes

Por Woerle, Hans Juergen, Carneiro, Lucianno, Derani, Ayman, Göke, Burkhard, Schirra, Jörg
Publicado em 2012

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

Por Johansen, Odd Erik, Neubacher, Dietmar, von Eynatten, Maximilian, Patel, Sanjay, Woerle, Hans-Juergen
Publicado em 2012

Pharmacokinetics of linagliptin in subjects with hepatic impairment

Por Graefe-Mody, Ulrike, Rose, Peter, Retlich, Silke, Ring, Arne, Waldhauser, Lisa, Cinca, Rodica, Woerle, Hans-Juergen
Publicado em 2012

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

Por Groop, Per-Henrik, Cooper, Mark E., Perkovic, Vlado, Emser, Angela, Woerle, Hans-Juergen, von Eynatten, Maximilian
Publicado em 2013

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials

Por Davidson, Jaime A, Lajara, Rosemarie, Aguilar, Richard B, Mattheus, Michaela, Woerle, Hans-Juergen, von Eynatten, Maximilian
Publicado em 2014

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Por Rosenstock, Julio, Marx, Nikolaus, Neubacher, Dietmar, Seck, Thomas, Patel, Sanjay, Woerle, Hans-Juergen, Johansen, Odd Erik
Publicado no Cardiovasc Diabetol (2015)

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

Por McGill, Janet B., Sloan, Lance, Newman, Jennifer, Patel, Sanjay, Sauce, Christophe, von Eynatten, Maximilian, Woerle, Hans-Juergen
Publicado em 2013

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Por Ferrannini, Ele, Muscelli, Elza, Frascerra, Silvia, Baldi, Simona, Mari, Andrea, Heise, Tim, Broedl, Uli C., Woerle, Hans-Juergen
Publicado em 2014

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Por Ferrannini, Ele, Muscelli, Elza, Frascerra, Silvia, Baldi, Simona, Mari, Andrea, Heise, Tim, Broedl, Uli C., Woerle, Hans-Juergen
Publicado em 2014

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin

Por Zimdahl, Heike, Ittrich, Carina, Graefe-Mody, Ulrike, Boehm, Bernhard O., Mark, Michael, Woerle, Hans-Juergen, Dugi, Klaus A.
Publicado em 2014

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study

Por Yki-Järvinen, Hannele, Rosenstock, Julio, Durán-Garcia, Santiago, Pinnetti, Sabine, Bhattacharya, Sudipta, Thiemann, Sandra, Patel, Sanjay, Woerle, Hans-Juergen
Publicado em 2013

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial

Por Chen, Yuhong, Ning, Guang, Wang, Changjiang, Gong, Yan, Patel, Sanjay, Zhang, Candice, Izumoto, Toshiyasu, Woerle, Hans-Juergen, Wang, Weiqing
Publicado no J Diabetes Investig (2015)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

Por Rauch, Thomas, Graefe-Mody, Ulrike, Deacon, Carolyn F., Ring, Arne, Holst, Jens J., Woerle, Hans-Juergen, Dugi, Klaus A., Heise, Tim
Publicado em 2012

Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus

Por Friedrich, Christian, Glund, Stephan, Lionetti, Dominick, Kissling, C James, Righetti, Julian, Patel, Sanjay, Graefe-Mody, Ulrike, Retlich, Silke, Woerle, Hans-Juergen
Publicado em 2013

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Por Cherney, David ZI, Perkins, Bruce A, Soleymanlou, Nima, Har, Ronnie, Fagan, Nora, Johansen, Odd Erik, Woerle, Hans-Juergen, von Eynatten, Maximilian, Broedl, Uli C
Publicado em 2014

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

Por Wanner, Christoph, Heerspink, Hiddo J.L., Zinman, Bernard, Inzucchi, Silvio E., Koitka-Weber, Audrey, Mattheus, Michaela, Hantel, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., von Eynatten, Maximilian, Groop, Per-Henrik
Publicado no J Am Soc Nephrol (2018)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Por Zinman, Bernard, Inzucchi, Silvio E, Lachin, John M, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Kempthorne-Rawson, Joan, Newman, Jennifer, Johansen, Odd Erik, Woerle, Hans-Juergen, Broedl, Uli C
Publicado em 2014

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(®))

Por Marx, Nikolaus, Rosenstock, Julio, Kahn, Steven E, Zinman, Bernard, Kastelein, John J, Lachin, John M, Espeland, Mark A, Bluhmki, Erich, Mattheus, Michaela, Ryckaert, Bart, Patel, Sanjay, Johansen, Odd Erik, Woerle, Hans-Juergen
Publicado no Diab Vasc Dis Res (2015)